[Form 4] AtriCure, Inc. Insider Trading Activity

Rhea-AI Filing Summary

On 30 June 2025, AtriCure, Inc. (ATRC) Chief Legal Officer Karl S. Dahlquist acquired 822 common shares through the company’s 2018 Employee Stock Purchase Plan (ESPP). The purchase price was $25.84, reflecting the plan’s 15% discount from the closing price of $30.40 on 2 January 2025, the first trading day of the offering period. Following the transaction, Dahlquist directly owns 68,551 ATRC shares. The Form 4 was signed on 2 July 2025 and indicates a routine, plan-based acquisition with no shares sold or disposed of.

Insights

Securities Analyst

TL;DR: Routine ESPP purchase of 822 shares by ATRC CLO; immaterial to valuation, signals ongoing insider participation.

The reported acquisition is small—about $21 k—and executed under AtriCure’s ESPP, a non-discretionary program that automatically enrolls eligible employees. Because the transaction adds roughly 1.2% to the officer’s existing 68.5 k-share position and involves no open-market buying or selling, it is unlikely to influence market perception or the firm’s risk profile. Such plan-based purchases are generally viewed as neutral: they confirm continued employee alignment but do not constitute a deliberate vote of confidence in the stock. Therefore, I classify the filing as non-impactful for investors.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doraiswamy Vinayak

(Last) (First) (Middle)

7555 INNOVATION WAY

(Street)

MASON OH 45040-9695

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AtriCure, Inc. [ ATRC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/30/2025		A		822(1)	A	$25.84(2)	74,372	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2025.

2. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 2, 2025, which is the first trading day of the applicable offering period. The closing price on January 2, 2025 was $30.40.

Remarks:

	/s/ Allison Walker as Attorney-in-fact for Vinayak S. Doraiswamy	07/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many ATRC shares did Karl S. Dahlquist purchase on 30 June 2025?

He acquired 822 common shares of AtriCure, Inc.

What price was paid for the ATRC shares under the ESPP?

The shares were purchased at $25.84, representing 85% of the 2 Jan 2025 closing price.

How many ATRC shares does Dahlquist own after the transaction?

His direct beneficial ownership increased to 68,551 shares.

Was this an open-market purchase or part of a plan?

It was a plan-based acquisition under AtriCure’s 2018 ESPP.

When was the Form 4 filed with the SEC?

The Form 4 was signed and filed on 2 July 2025.